Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL)
COLLEGIUM PHARMACEUTICAL, INC. director Carlos V. Paya was granted 8,741 restricted stock units (RSUs) as compensation, increasing his direct holdings to 28,323 shares. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, contingent on his continued board service. The grant price was $0.00, and the settlement will be in common stock shares upon vesting or under specific conditions like the end of his board service or a change in control.
How this was made
The 30-second read
Why it matters
This insider activity is routine and does not indicate any immediate corporate changes or strategic shifts.
Market read
The news has limited impact on the company's stock price or market perception; primarily relevant for understanding insider compensation practices.
What to watch
The grant's value is small relative to the company's market cap; broader market conditions and upcoming catalysts are more influential.
Background
Carlos V. Paya, a director of Collegium Pharmaceutical, received 8,741 RSUs as part of his compensation package, vesting over time or upon certain events.
Ticker impact
The news pertains directly to the company's insider activity, which can influence investor perception and stock price.
Minimal to no immediate impact; potential slight positive sentiment if perceived as confidence indication.
Insider grants are routine and do not necessarily indicate upcoming positive or negative price movements. The grant's value is minimal relative to market capitalization, and the timing is not aligned with major corporate events.
Market effects
Limited; the news does not suggest sector-wide changes.
Minimal; specific to company insiders and not affecting regional markets.
Negligible; company-specific insider activity.
Counterpoint
Some investors might interpret insider grants as a sign of management's confidence, potentially supporting the stock.
Key entities
- PersonCarlos V. Paya
Director of Collegium Pharmaceutical receiving RSUs.
- CompanyCOLL
Collegium Pharmaceutical, NASDAQ-listed biopharmaceutical company.
